Inventor · disambiguated record
Boris Engels
Also filed as: ENGELS BORIS
16 granted patents·13 pending applications·85 citations·filing 2014–2025
92Inventor score
Top patents by PatentIndex Score
29 records- 0196US10525083B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2017·Granted Jan 7, 2020·15 cites·33 claims
- 0294US11975026B2CD19 and CD22 chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted May 7, 2024·3 cites·23 claims
- 0394US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 0494US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 0593US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 0693US10640569B2Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2014·Granted May 5, 2020·15 cites·49 claims
- 0792US12344651B2CD19 and CD22 chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Granted Jul 1, 2025·1 cites·12 claims
- 0892US10577417B2Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2015·Granted Mar 3, 2020·10 cites·33 claims
- 0986US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 1085US2025011461A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1183US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 1282US2024294662A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1380US12383601B2Chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted Aug 12, 2025·1 cites·21 claims
- 1479USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 1578US2024317850A1Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1676US12186278B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2022·Granted Jan 7, 2025·0 cites·27 claims
- 1772US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1867US11999794B2Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted Jun 4, 2024·0 cites·21 claims
- 1966US2025319179A1Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 2062US11981731B2Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2020·Granted May 14, 2024·0 cites·17 claims
- 2160US2021087279A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2247US2023256017A1Methods of making chimeric antigen receptor-expressing cellsBROGDON JENNIFER·Filed 2021·Application pending·0 cites
- 2346US2017081411A1Regulatable chimeric antigen receptorENGELS BORIS·Filed 2015·Application pending·0 cites
- 2445US2023174933A1Methods of making chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2544US2022364055A1Methods of making chimeric antigen receptor-expressing cellsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2641US10189908B2Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variantsUNIV CHICAGO·Filed 2015·Granted Jan 29, 2019·0 cites·18 claims
- 2739US2020371091A1Bcma-targeting chimeric antigen receptor, and uses thereofNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2838US2019375815A1Treatment of cancer using chimeric t cell receptor proteins having multiple specificitiesNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2930US2017145108A1Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variantsUNIV CHICAGO·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Boris Engels files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →